Search

Your search keyword '"Miao, Lei"' showing total 2,228 results
Start Over Author "Miao, Lei"
2,228 results on '"Miao, Lei"'

52. Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia

Author

JI Xiaojun, ZHAO Tingli, MIAO Lei, SI Yaxuan, WU Jian, and XU Dan

Subjects
aml, targeted therapy, immunotherapy, drug progress, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Targeted therapeutic drugs for acute myeloid leukemia (AML) are showing immense development, thereby laying a solid foundation for the precise treatment of AML patients. The paper reviews four types of targeted drugs that have progressed rapidly for AML treatment (by targeting genes or signaling-pathway alterations, targeting apoptosis-related pathways, targeting cell-surface antigens, and targeting immune-related substances). We look forward to the future development directions of targeted drugs, providing references for hematologists and developers of new drugs for AML.

Published
2023
Full Text
View/download PDF

76. Does Population Aging Affect the Rebound of Fertility?

Author

Miao, Lei, Huang, Cheng, Striełkowski, Wadim, Editor-in-Chief, Black, Jessica M., Series Editor, Butterfield, Stephen A., Series Editor, Chang, Chi-Cheng, Series Editor, Cheng, Jiuqing, Series Editor, Dumanig, Francisco Perlas, Series Editor, Al-Mabuk, Radhi, Series Editor, Scheper-Hughes, Nancy, Series Editor, Urban, Mathias, Series Editor, Webb, Stephen, Series Editor, Ali, Ghaffar, editor, Birkök, Mehmet Cüneyt, editor, and Khan, Intakhab Alam, editor

Published
2022
Full Text
View/download PDF

90. Yes-associated protein inhibition ameliorates liver fibrosis and acute and chronic liver failure by decreasing ferroptosis and necroptosis

Author

Wen Zhao, Miao Lei, Jinfeng Li, Hailin Zhang, Hongkun Zhang, Yuxin Han, Zhiwei Ba, Manli Zhang, Dongdong Li, and Chuanmiao Liu

Subjects
Liver cirrhosis, Acute-on-chronic liver failure, Yes-associated protein, Ferroptosis, Necroptosis, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Background/aims: This study aims to determine which cell death modes contribute most in the progression of cirrhosis and acute-on-chronic liver failure (ACLF), and to investigate whether Yes associated protein (YAP) affects the disease process by regulating cell death. Materials and methods: 30C57BL/6 male mice were divided into five groups: control, carbon tetrachloride (CCl4)-induced liver fibrosis model, CCl4+verteporfin, CCl4+lipopolysaccharides (LPS) combined with the D-(+)-Galactosamine (LPS/D-GalN)-induced ACLF model, and ACLF + verteporfin. Patients with chronic hepatitis B (CHB), hepatitis B virus (HBV) related liver cirrhosis or ACLF were enrolled. Histology, immunohistochemistry, transmission electron microscopy, Western blot and ELISA were conducted to assess the roles of YAP and cell death in liver cirrhosis and ACLF, and to explore the effect of YAP inhibition on cell deaths. Results: YAP was markedly increased in mice with liver fibrosis and ACLF, along with ferroptosis and necroptosis. Furthermore, YAP inhibition significantly suppressed fibrosis in CCl4-mediated liver fibrosis and ACLF-associated liver injury. Notably, CCl4 induced up-regulation of ACSL4 and RIPK3 and down-regulation of SLC7A11, key factors in ferroptosis and necroptosis. This was significantly abrogated by verteporfin treatment. Similar changes in ferroptosis and necroptosis were found in ACLF and ACLF + verteporfin groups. Consistent with the above findings in mice, we found that plasma YAP levels were gradually increased with the development of HBV-related liver fibrosis and ACLF. Conclusion: Ferroptosis and necroptosis are involved in the development of liver cirrhosis and ACLF. Inhibition of YAP improved liver fibrosis and liver damage in ACLF through a reduction in ferroptosis and necroptosis. Our findings may help better understanding the role of YAP in liver fibrosis and ACLF.

Published
2023
Full Text
View/download PDF

92. Optimal On-Off Control for a Class of Discrete Event Systems with Real-Time Constraints

Author

Miao, Lei, Xu, Lijian, and Jiang, Dingde

Subjects
Mathematics - Optimization and Control
Abstract

This paper studies an optimal ON-OFF control problem for a class of discrete event systems with real-time constraints. Our goal is to minimize the overall costs, including the operating cost and the wake-up cost, while still guaranteeing the deadline of each individual task. In particular, we consider the homogeneous case in which it takes the same amount of time to serve each task and each task needs to be served by d seconds upon arrival. The problem involves two subproblems: (i) finding the best time to wake up the system and (ii) finding the best time to let the system go to sleep. We study the two subproblems in both off-line and on-line settings. In the off-line case that all task information is known a priori, we combine sample path analysis and dynamic programming to come up with the optimal solution. In the on-line scenario where future task information is completely unknown, we show that the optimal time to wake up the system can be obtained without relying on future task arrivals. We also perform competitive analysis for on-line control and derive the competitive ratios for both deterministic and random controllers.

Published
2018

99. Mutation Genes in Common Tumors of Digestive System and Druggability of New Targets

Author

JI Xiaojun, MIAO Lei, MA Changyou, TANG Ying, ZHOU Qiuhua, WU Jian, and XU Dan

Subjects
digestive system tumors, driver genes, mutant genes, targets, druggability, new drugs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective To establish a druggability evaluation method for new targets of anti-tumor drugs by analyzing the mutation genes of common tumors in the digestive system. Methods We collected the mutant gene data of the five common tumors of the digestive system (esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) in the Integrative Onco Genomics database, and screened out the genes with higher mutation rates in each tumor. We evaluated the druggability of these genes or their encoded proteins, and discovered the potential targets for the new anti-tumor drugs. Results A total of five tumors, 35 cohorts and 5445 tumor samples were collected in this study. The top 10 mutation genes were selected for further analysis. The canSAR database was used to analyze the druggability of unpublished mutant genes or their encoded proteins, and a total of 17 potential therapeutic drug targets were screened out. Conclusion A method for evaluating druggability of targets based on mutant genes or their encoded protein is established in this study. The application of this method can provide a reference for discovering new anti-tumor therapeutic target, saving the cost and time of target screening in new drug development.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results